Regeneron On Genetics R&D: 'It's Our Oxygen'

Regeneron is pointing to early research in genetics as the lifeline that will deliver new drugs into the clinic as Eylea matures, new blockbusters have yet to materialize and investors grow restless.

Genetics lab at Regeneron with robotic arm
Inside the lab at the Regeneron Genetics Center

Regeneron Pharmaceuticals Inc. is promoting its early genetics research as the backbone of its R&D organization, providing a powerful advantage over rivals that will deliver a new wave of medicines into the clinic and eventually to market.

Regeneron is talking up its early research at the Regeneron Genetics Center (RGC) at a time when the company's big-seller Eylea (aflibercept) is maturing, new blockbusters have not materialized and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip